Search

Your search keyword '"Juliusson, Gunnar"' showing total 155 results
Start Over Author "Juliusson, Gunnar" Publication Year Range Last 3 years
155 results on '"Juliusson, Gunnar"'

1. Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Author

Grever, Michael, Andritsos, Leslie, Anghelina, Mirela, Arons, Evgeny, Banerji, Versha, Barrientos, Jacqueline, Bhat, Seema A., Blachly, James, Broccoli, Alessandro, Call, Timothy, Dearden, Claire, Dietrich, Sascha, Else, Monica, Epperla, Narendranath, Fagarasanu, Andrei, Falini, Brunangelo, Forconi, Francesco, Gozzetti, Alessandro, Hampel, Paul, Hermel, David J., Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Oakes, Christopher C., Parikh, Sameer A., Park, Jae, Quest, Graeme, Rai, Kanti, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Wörmann, Bernhard, Zent, Clive S., Zenz, Thorsten, and Zinzani, Pier Luigi

Published
2024
Full Text
View/download PDF

2. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Author

Fürstenau, Moritz, Kater, Arnon P, Robrecht, Sandra, von Tresckow, Julia, Zhang, Can, Gregor, Michael, Thornton, Patrick, Staber, Philipp B, Tadmor, Tamar, Lindström, Vesa, Juliusson, Gunnar, Janssens, Ann, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Goldschmidt, Neta, Vandenberghe, Elisabeth, Rossi, Davide, Benz, Rudolf, Nösslinger, Thomas, Heintel, Daniel, Poulsen, Christian B, Christiansen, Ilse, Frederiksen, Henrik, Enggaard, Lisbeth, Posthuma, Eduardus F M, Issa, Djamila E, Visser, Hein P J, Bellido, Mar, Kutsch, Nadine, Dürig, Jan, Stehle, Alexander, Vöhringer, Matthias, Böttcher, Sebastian, Schulte, Clemens, Simon, Florian, Fink, Anna-Maria, Fischer, Kirsten, Holmes, Emily E, Kreuzer, Karl-Anton, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Hallek, Michael, Niemann, Carsten U, and Eichhorst, Barbara

Published
2024
Full Text
View/download PDF

3. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Author

Fürstenau, Moritz, Thus, Yvonne J., Robrecht, Sandra, Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie, von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjoern, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Nösslinger, Thomas, Baumann, Michael, Hebart, Holger, Gaska, Tobias, Regelink, Josien C., Dompeling, Ellen C., Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Spaargaren, Marcel, Eldering, Eric, Stilgenbauer, Stephan, Niemann, Carsten U., Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Published
2023
Full Text
View/download PDF

6. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Author

Ravandi, Farhad, Kreitman, Robert J., Tiacci, Enrico, Andritsos, Leslie, Banerji, Versha, Barrientos, Jacqueline C., Bhat, Seema A., Blachly, James S., Broccoli, Alessandro, Call, Timothy, Chihara, Dai, Dearden, Claire, Demeter, Judit, Dietrich, Sasha, Else, Monica, Epperla, Narendranath, Falini, Brunangelo, Forconi, Francesco, Gladstone, Douglas E., Gozzetti, Alessandro, Iyengar, Sunil, Johnston, James B., Jorgensen, Jeffrey, Juliusson, Gunnar, Lauria, Francesco, Lozanski, Gerard, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Thompson, Philip A., Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, Wörmann, Bernhard, Rai, Kanti, and Grever, Michael

Published
2022
Full Text
View/download PDF

7. Complex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden.

Author

Hemminki, Kari, Zitricky, Frantisek, Försti, Asta, Tapaninen, Tuija, Hemminki, Akseli, Juliusson, Gunnar, and Niemann, Carsten Utoft

Subjects
CHRONIC lymphocytic leukemia diagnosis, CHRONIC lymphocytic leukemia, MORTALITY, RESEARCH funding, SEX distribution, AGE distribution, DESCRIPTIVE statistics, CHRONIC diseases
Abstract

Simple Summary: Chronic lymphocytic leukemia (CLL) is a common leukemia characterized by an accumulation of lymphocytes in the blood and lymphoid organs. Disease presentation is highly variable as many patients do not initially require any treatment, and a watch and wait strategy remains the standard of care for up to 50% of patients. However, for those with a progressive disease, chemotherapy is the standard treatment and has improved over the years, increasing the survival of patients. We analyze here age-specific relative survival trends in CLL through 50 years up to 2020s in Denmark, Finland, Norway, and Sweden using the NORDCAN database. The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89-years, survival improved later, reaching 90% in Denmark and less in the other countries. Survival in Denmark is probably among the best in the world, which could be achieved by boosting survival even among the oldest patients. Most Nordic survival rates were better than those in the USA. Background: Chronic lymphocytic leukemia (CLL) is a common hematological malignancy with highly variable clinical presentation. Many patients never require any treatment but for the others, chemotherapy, immunochemotherapy, and newer targeted therapies have changed the treatment landscape. Diagnostic age influences the applied treatment, and we thus wanted to analyze age-specific survival trends through 50 years up to 2020s. Methods: We used 1- and 5-year relative survival from the NORDCAN database, with data from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE). Because of the variable presentation of CLL, we also considered incidence and mortality trends. For comparison, US SEER data were used. Results: The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89 years, survival reached 90% in DK and SE women, 80% in NO and SE men, but only 50% in FI. DK 5-year overall survival for men was 92.4%, and for women, it was 96.3%. These survival figures were higher than age-group-specific US survival data. Conclusions: The DK data are probably global top figures for national survival which could be achieved by boosting survival even among the oldest patients. The qualification to these figures and international comparisons is that survival needs to be considered in terms of incidence, which is high in DK and NO. Low survival of the FI 80–89-year-old patients, even in the first year after diagnosis, may suggest delayed diagnosis, which should call for a closer national scrutiny. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture‐Based Gene Panel.

Author

Orsmark‐Pietras, Christina, Lyander, Anna, Ladenvall, Claes, Hallström, Björn, Staffas, Anna, Awier, Hero, Krstic, Aleksandra, Baliakas, Panagiotis, Barbany, Gisela, Håkansson, Cecilia Brunhoff, Gellerbring, Anna, Hagström, Anna, Hellström‐Lindberg, Eva, Juliusson, Gunnar, Lazarevic, Vladimir, Munters, Arielle, Pandzic, Tatjana, Wadelius, Mia, Ås, Joel, and Fogelstrand, Linda

Published
2024
Full Text
View/download PDF

11. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial

Author

Ngai, Lok Lam, Hanekamp, Diana, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A M, Fayed, Mona M H E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J, Snel, Alexander N, Bachas, Costa, Tettero, Jesse M, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Griskevicius, Laimonas, Juliusson, Gunnar, van de Loosdrecht, Arjan A, Maertens, Johan A, Manz, Markus G, Pabst, Thomas, Passweg, Jakob R, Porkka, Kimmo, Valk, Peter J M, Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David C, Janssen, Jeroen J W M, Ossenkoppele, Gert J, Cloos, Jacqueline, Hematology laboratory, VU University medical center, Hematology, AII - Cancer immunology, AII - Inflammatory diseases, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, and CCA - Cancer Treatment and quality of life

Subjects
All institutes and research themes of the Radboud University Medical Center, Immunology, Cell Biology, Hematology, 610 Medicine & health, Biochemistry, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Item does not contain fulltext

Published
2023

12. P513: MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY.

Author

Juliusson, Gunnar, primary, Nilsson, Christer, additional, Lehmann, Sören, additional, Jädersten, Martin, additional, Wennström, Lovisa, additional, Fogelstrand, Linda, additional, Baliakas, Panagiotis, additional, Pandzic, Tatjana, additional, Cavelier, Lucia, additional, Eriksson, Anna, additional, Österroos, Albin, additional, Thunström, Anna, additional, Piauger, Benedicte, additional, Uggla, Bertil, additional, Ölander, Emma, additional, Orrsjö, Gustav, additional, Cammenga, Jörg, additional, Myhr-Eriksson, Kristina, additional, Willner Hjelm, Petter, additional, Deneberg, Stefan, additional, Fioretos, Thoas, additional, Höglund, Martin, additional, and Lazarevic, Vladimir, additional

Published
2023
Full Text
View/download PDF

13. P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL

Author

Tettero, Jesse, primary, Palmieri, Raffaele, additional, Lam Ngai, Lok, additional, Bachas, Costa, additional, Arena, Valentina, additional, Breems, Dimitri, additional, Fischer, Thomas, additional, Tore Gjertsen, Bjorn, additional, Griškevičius, Laimonas, additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus, additional, Maurillo, Luca, additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Piciocchi, Alfonso, additional, Porkka, Kimmo, additional, Löwenberg, Bob, additional, Venditti, Adriano, additional, Ossenkoppele, Gert, additional, Buccisano, Francesco, additional, and Cloos, Jacqueline, additional

Published
2023
Full Text
View/download PDF

14. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.

Author

Lam Ngai, Lok, primary, Hanekamp, Diana, additional, Kelder, Angèle, additional, Scholten, Willemijn J., additional, Carbaat - Ham, Jannemieke, additional, Snel, Alexander N., additional, Bachas, Costa, additional, Tettero, Jesse, additional, van der Velden, Vincent, additional, Slomp, Jennichjen, additional, Hobo, Willemijn, additional, Breems, Dimitri, additional, Fischer, Thomas, additional, Tore Gjertsen, Bjorn, additional, Griškevičius, Laimonas, additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus, additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Porkka, Kimmo, additional, Valk, Peter, additional, Gradowska, Patrycja, additional, Löwenberg, Bob, additional, de Leeuw, David, additional, van de Loosdrecht, Arjan, additional, Ossenkoppele, Gert, additional, and Cloos, Jacqueline, additional

Published
2023
Full Text
View/download PDF

15. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Author

Eichhorst, Barbara, primary, Niemann, Carsten U., additional, Kater, Arnon P., additional, Fürstenau, Moritz, additional, von Tresckow, Julia, additional, Zhang, Can, additional, Robrecht, Sandra, additional, Gregor, Michael, additional, Juliusson, Gunnar, additional, Thornton, Patrick, additional, Staber, Philipp B., additional, Tadmor, Tamar, additional, Lindström, Vesa, additional, da Cunha-Bang, Caspar, additional, Schneider, Christof, additional, Poulsen, Christian B., additional, Illmer, Thomas, additional, Schöttker, Björn, additional, Nösslinger, Thomas, additional, Janssens, Ann, additional, Christiansen, Ilse, additional, Baumann, Michael, additional, Frederiksen, Henrik, additional, van der Klift, Marjolein, additional, Jäger, Ulrich, additional, Leys, Maria B.L., additional, Hoogendoorn, Mels, additional, Lotfi, Kourosh, additional, Hebart, Holger, additional, Gaska, Tobias, additional, Koene, Harry, additional, Enggaard, Lisbeth, additional, Goede, Jereon, additional, Regelink, Josien C., additional, Widmer, Anouk, additional, Simon, Florian, additional, De Silva, Nisha, additional, Fink, Anna-Maria, additional, Bahlo, Jasmin, additional, Fischer, Kirsten, additional, Wendtner, Clemens-Martin, additional, Kreuzer, Karl A., additional, Ritgen, Matthias, additional, Brüggemann, Monika, additional, Tausch, Eugen, additional, Levin, Mark-David, additional, van Oers, Marinus, additional, Geisler, Christian, additional, Stilgenbauer, Stephan, additional, and Hallek, Michael, additional

Published
2023
Full Text
View/download PDF

16. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms

Author

Grever, Michael, Andritsos, Leslie, Anghelina, Mirela, Arons, Evgeny, Banerji, Versha, Barrientos, Jacqueline, Bhat, Seema A., Blachly, James, Broccoli, Alessandro, Call, Timothy, Dearden, Claire, Dietrich, Sascha, Else, Monica, Epperla, Narendranath, Fagarasanu, Andrei, Falini, Brunangelo, Forconi, Francesco, Gozzetti, Alessandro, Hampel, Paul, Hermel, David J., Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Oakes, Christopher C., Parikh, Sameer A., Park, Jae, Quest, Graeme, Rai, Kanti, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Wörmann, Bernhard, Zent, Clive S., Zenz, Thorsten, and Zinzani, Pier Luigi

Published
2024
Full Text
View/download PDF

17. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Author

Tettero, Jesse M., primary, Ngai, Lok Lam, additional, Bachas, Costa, additional, Breems, Dimitri A., additional, Fischer, Thomas, additional, Gjertsen, Bjorn T., additional, Gradowska, Patrycja, additional, Griskevicius, Laimonas, additional, Janssen, Jeroen J.W.M., additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus G., additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Porkka, Kimmo, additional, Valk, Peter J.M., additional, Löwenberg, Bob, additional, Ossenkoppele, Gert J., additional, and Cloos, Jacqueline, additional

Published
2023
Full Text
View/download PDF

18. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Author

Xochelli, Aliki, primary, Baliakas, Panagiotis, primary, Kavakiotis, Ioannis, primary, Agathangelidis, Andreas, primary, Sutton, Lesley-Ann, primary, Minga, Eva, primary, Ntoufa, Stavroula, primary, Tausch, Eugen, primary, Yan, Xiao-Jie, primary, Shanafelt, Tait, primary, Plevova, Karla, primary, Boudjogra, Myriam, primary, Rossi, Davide, primary, Davis, Zadie, primary, Navarro, Alba, primary, Sandberg, Yorick, primary, Vojdeman, Fie Juhl, primary, Scarfo, Lydia, primary, Stavroyianni, Niki, primary, Sudarikov, Andrey, primary, Veronese, Silvio, primary, Tzenou, Tatiana, primary, Karan-Djurasevic, Teodora, primary, Catherwood, Mark, primary, Kienle, Dirk, primary, Chatzouli, Maria, primary, Facco, Monica, primary, Bahlo, Jasmin, primary, Pott, Christiane, primary, Pedersen, Lone Bredo, primary, Mansouri, Larry, primary, Smedby, Karin E., primary, Chu, Charles C., primary, Giudicelli, Véronique, primary, Lefranc, Marie-Paule, primary, Panagiotidis, Panagiotis, primary, Juliusson, Gunnar, primary, Anagnostopoulos, Achilles, primary, Vlahavas, Ioannis, primary, Antic, Darko, primary, Trentin, Livio, primary, Montillo, Marco, primary, Niemann, Carsten, primary, Döhner, Hartmut, primary, Langerak, Anton W., primary, Pospisilova, Sarka, primary, Hallek, Michael, primary, Campo, Elias, primary, Chiorazzi, Nicholas, primary, Maglaveras, Nikos, primary, Oscier, David, primary, Gaidano, Gianluca, primary, Jelinek, Diane F., primary, Stilgenbauer, Stephan, primary, Chouvarda, Ioanna, primary, Darzentas, Nikos, primary, Belessi, Chrysoula, primary, Davi, Frederic, primary, Hadzidimitriou, Anastasia, primary, Rosenquist, Richard, primary, Ghia, Paolo, primary, and Stamatopoulos, Kostas, primary

Published
2023
Full Text
View/download PDF

19. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Author

Xochelli, Aliki, primary, Baliakas, Panagiotis, primary, Kavakiotis, Ioannis, primary, Agathangelidis, Andreas, primary, Sutton, Lesley-Ann, primary, Minga, Eva, primary, Ntoufa, Stavroula, primary, Tausch, Eugen, primary, Yan, Xiao-Jie, primary, Shanafelt, Tait, primary, Plevova, Karla, primary, Boudjogra, Myriam, primary, Rossi, Davide, primary, Davis, Zadie, primary, Navarro, Alba, primary, Sandberg, Yorick, primary, Vojdeman, Fie Juhl, primary, Scarfo, Lydia, primary, Stavroyianni, Niki, primary, Sudarikov, Andrey, primary, Veronese, Silvio, primary, Tzenou, Tatiana, primary, Karan-Djurasevic, Teodora, primary, Catherwood, Mark, primary, Kienle, Dirk, primary, Chatzouli, Maria, primary, Facco, Monica, primary, Bahlo, Jasmin, primary, Pott, Christiane, primary, Pedersen, Lone Bredo, primary, Mansouri, Larry, primary, Smedby, Karin E., primary, Chu, Charles C., primary, Giudicelli, Véronique, primary, Lefranc, Marie-Paule, primary, Panagiotidis, Panagiotis, primary, Juliusson, Gunnar, primary, Anagnostopoulos, Achilles, primary, Vlahavas, Ioannis, primary, Antic, Darko, primary, Trentin, Livio, primary, Montillo, Marco, primary, Niemann, Carsten, primary, Döhner, Hartmut, primary, Langerak, Anton W., primary, Pospisilova, Sarka, primary, Hallek, Michael, primary, Campo, Elias, primary, Chiorazzi, Nicholas, primary, Maglaveras, Nikos, primary, Oscier, David, primary, Gaidano, Gianluca, primary, Jelinek, Diane F., primary, Stilgenbauer, Stephan, primary, Chouvarda, Ioanna, primary, Darzentas, Nikos, primary, Belessi, Chrysoula, primary, Davi, Frederic, primary, Hadzidimitriou, Anastasia, primary, Rosenquist, Richard, primary, Ghia, Paolo, primary, and Stamatopoulos, Kostas, primary

Published
2023
Full Text
View/download PDF

20. Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications

Author

Nilsson, Christer, Linde, Fredrika, Hulegardh, Erik, Garelius, Hege, Lazarevic, Vladimir, Antunovic, Petar, Cammenga, Jorg, Deneberg, Stefan, Eriksson, Anna, Jadersten, Martin, Bjorkvall, Cecilia Kampe, Mollgard, Lars, Wennstrom, Lovisa, Olander, Emma, Höglund, Martin, Juliusson, Gunnar, Lehmann, Sören, Nilsson, Christer, Linde, Fredrika, Hulegardh, Erik, Garelius, Hege, Lazarevic, Vladimir, Antunovic, Petar, Cammenga, Jorg, Deneberg, Stefan, Eriksson, Anna, Jadersten, Martin, Bjorkvall, Cecilia Kampe, Mollgard, Lars, Wennstrom, Lovisa, Olander, Emma, Höglund, Martin, Juliusson, Gunnar, and Lehmann, Sören

Abstract

Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and reliable incidence rates are lacking. In this study, we characterized, defined the incidence over time and studied prognostic implications in all t-AML patients diagnosed in Sweden between 1997 and 2015. Data were retrieved from nationwide population-based registries. In total, 6,779 AML patients were included in the study, of whom 686 (10%) had t-AML. The median age for t-AML was 71 years and 392 (57%) patients were females. During the study period, the incidence of t-AML almost doubled with a yearly increase in t-AML of 4.5% (95% confidence interval: 2.8%-6.2%), which contributed significantly to the general increase in AML incidence over the study period. t-AML solidly constituted over 10% of all AML cases during the later period of the study. Primary diagnoses with the largest increase in incidence and decrease in mortality rate during the study period (i.e., breast and prostate cancer) contributed significantly to the increased incidence of t-AML. In multivariable analysis, t-AML was associated with poorer outcome in cytogenetically intermediate-and adverse-risk cases but t-AML had no significant impact on outcome in favorable-risk AML, including core binding leukemias, acute promyelocytic leukemia and AML with mutated NPM1 without FLT3-ITD. We conclude that there is a strong increase in incidence in t-AML over time and that t-AML constitutes a successively larger proportion of the AML cases. Furthermore, we conclude that t-AML confers a poor prognosis in cytogenetically intermediate-and adverse-risk, but not in favorable-risk AML.

Published
2023
Full Text
View/download PDF

21. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Author

Tettero, Jesse M., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., Fischer, Thomas, Gjertsen, Bjorn T., Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J.W.M., Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J.M., Löwenberg, Bob, Ossenkoppele, Gert J., Cloos, Jacqueline, Tettero, Jesse M., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., Fischer, Thomas, Gjertsen, Bjorn T., Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J.W.M., Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J.M., Löwenberg, Bob, Ossenkoppele, Gert J., and Cloos, Jacqueline

Published
2023

22. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Author

Eichhorst, Barbara, Niemann, Carsten U., Kater, Arnon P., Fuerstenau, Moritz, von Tresckow, Julia, Zhang, Can, Robrecht, Sandra, Gregor, Michael, Juliusson, Gunnar, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Lindstrom, Vesa, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian B., Illmer, Thomas, Schoettker, Bjoern, Noesslinger, Thomas, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Frederiksen, Henrik, van der Klift, Marjolein, Jaeger, Ulrich, Leys, Maria B. L., Hoogendoorn, Mels, Lotfi, Kourosh, Hebart, Holger, Gaska, Tobias, Koene, Harry, Enggaard, Lisbeth, Goede, Jereon, Regelink, Josien C., Widmer, Anouk, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl A., Ritgen, Matthias, Brueggemann, Monika, Tausch, Eugen, Levin, Mark-David, van Oers, Marinus, Geisler, Christian, Stilgenbauer, Stephan, Hallek, Michael, Eichhorst, Barbara, Niemann, Carsten U., Kater, Arnon P., Fuerstenau, Moritz, von Tresckow, Julia, Zhang, Can, Robrecht, Sandra, Gregor, Michael, Juliusson, Gunnar, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Lindstrom, Vesa, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian B., Illmer, Thomas, Schoettker, Bjoern, Noesslinger, Thomas, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Frederiksen, Henrik, van der Klift, Marjolein, Jaeger, Ulrich, Leys, Maria B. L., Hoogendoorn, Mels, Lotfi, Kourosh, Hebart, Holger, Gaska, Tobias, Koene, Harry, Enggaard, Lisbeth, Goede, Jereon, Regelink, Josien C., Widmer, Anouk, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl A., Ritgen, Matthias, Brueggemann, Monika, Tausch, Eugen, Levin, Mark-David, van Oers, Marinus, Geisler, Christian, Stilgenbauer, Stephan, and Hallek, Michael

Abstract

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. Methods In a phase 3, open-label trial, we randomly assigned, in a 1:1:1:1 ratio, fit patients with CLL who did not have TP53 aberrations to receive six cycles of chemoimmunotherapy (fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab) or 12 cycles of venetoclax-rituximab, venetoclax-obinutuzumab, or venetoclax-obinutuzumab-ibrutinib. Ibrutinib was discontinued after two consecutive measurements of undetectable minimal residual disease or could be extended. The primary end points were undetectable minimal residual disease (sensitivity, <10(-4) [i.e., <1 CLL cell in 10,000 leukocytes]) as assessed by flow cytometry in peripheral blood at month 15 and progression-free survival. Results A total of 926 patients were assigned to one of the four treatment regimens (229 to chemoimmunotherapy, 237 to venetoclax-rituximab, 229 to venetoclax-obinutuzumab, and 231 to venetoclax-obinutuzumab-ibrutinib). At month 15, the percentage of patients with undetectable minimal residual disease was significantly higher in the venetoclax-obinutuzumab group (86.5%; 97.5% confidence interval [CI], 80.6 to 91.1) and the venetoclax-obinutuzumab-ibrutinib group (92.2%; 97.5% CI, 87.3 to 95.7) than in the chemoimmunotherapy group (52.0%; 97.5% CI, 44.4 to 59.5; P<0.001 for both comparisons), but it was not significantly higher in the venetoclax-rituximab group (57.0%; 97.5% CI, 49.5 to 64.2; P=0.32). Three-year progression-free survival was 90.5% in the venetoclax-obinutuzumab-ibrutinib group and 75.5% in the chemoimmunotherapy group (hazard ratio for disease progression or death, 0.32; 97.5% CI, 0.19 to 0.54; P<0.001). Progression-free survival at 3 years was also higher with venetoclax-obinutuzumab (87.7%; hazard ratio for, Funding Agencies|AbbVie

Published
2023
Full Text
View/download PDF

23. Prospective validation of the prognostic relevance of CD34$^{+}$CD38$^{-}$ AML stem cell frequency in the HOVON-SAKK132 trial

Author

Ngai, Lok Lam; https://orcid.org/0000-0003-0969-3766, Hanekamp, Diana; https://orcid.org/0000-0002-5902-1127, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A M A, Fayed, Mona M H E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J, Snel, Alexander N, Bachas, Costa; https://orcid.org/0000-0001-5983-6193, Tettero, Jesse M; https://orcid.org/0000-0002-0811-0824, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjørn T; https://orcid.org/0000-0001-9358-9704, Griškevičius, Laimonas; https://orcid.org/0000-0002-3731-1537, Juliusson, Gunnar; https://orcid.org/0000-0002-7911-7265, van de Loosdrecht, Arjan A; https://orcid.org/0000-0001-8311-983X, Maertens, Johan A; https://orcid.org/0000-0003-4257-5980, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas; https://orcid.org/0000-0002-6055-5257, Passweg, Jakob R; https://orcid.org/0000-0001-7092-3351, Porkka, Kimmo; https://orcid.org/0000-0003-4112-5902, Valk, Peter J M; https://orcid.org/0000-0002-8857-9461, Gradowska, Patrycja; https://orcid.org/0000-0002-4620-9163, Löwenberg, Bob; https://orcid.org/0000-0001-8982-5217, de Leeuw, David C; https://orcid.org/0000-0003-4591-8467, Janssen, Jeroen J W M, Ossenkoppele, Gert J, Cloos, Jacqueline; https://orcid.org/0000-0001-9150-8026, Ngai, Lok Lam; https://orcid.org/0000-0003-0969-3766, Hanekamp, Diana; https://orcid.org/0000-0002-5902-1127, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A M A, Fayed, Mona M H E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J, Snel, Alexander N, Bachas, Costa; https://orcid.org/0000-0001-5983-6193, Tettero, Jesse M; https://orcid.org/0000-0002-0811-0824, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjørn T; https://orcid.org/0000-0001-9358-9704, Griškevičius, Laimonas; https://orcid.org/0000-0002-3731-1537, Juliusson, Gunnar; https://orcid.org/0000-0002-7911-7265, van de Loosdrecht, Arjan A; https://orcid.org/0000-0001-8311-983X, Maertens, Johan A; https://orcid.org/0000-0003-4257-5980, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas; https://orcid.org/0000-0002-6055-5257, Passweg, Jakob R; https://orcid.org/0000-0001-7092-3351, Porkka, Kimmo; https://orcid.org/0000-0003-4112-5902, Valk, Peter J M; https://orcid.org/0000-0002-8857-9461, Gradowska, Patrycja; https://orcid.org/0000-0002-4620-9163, Löwenberg, Bob; https://orcid.org/0000-0001-8982-5217, de Leeuw, David C; https://orcid.org/0000-0003-4591-8467, Janssen, Jeroen J W M, Ossenkoppele, Gert J, and Cloos, Jacqueline; https://orcid.org/0000-0001-9150-8026

Published
2023

24. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Author

Tettero, Jesse M, Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J W M, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J M; https://orcid.org/0000-0002-8857-9461, Löwenberg, Bob; https://orcid.org/0000-0001-8982-5217, Ossenkoppele, Gert J, Cloos, Jacqueline, Tettero, Jesse M, Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J W M, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J M; https://orcid.org/0000-0002-8857-9461, Löwenberg, Bob; https://orcid.org/0000-0001-8982-5217, Ossenkoppele, Gert J, and Cloos, Jacqueline

Published
2023

26. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML

Author

von Palffy, Sofia, primary, Thorsson, Hanna, additional, Peña-Martínez, Pablo, additional, PUENTE-MONCADA, NOELIA, additional, Sandén, Carl, additional, Blom, Anna M, additional, Henningsson, Rasmus, additional, Juliusson, Gunnar, additional, King, Ben C, additional, Landberg, Niklas, additional, Lazarevic, Vladimir Lj, additional, Orsmark-Pietras, Christina, additional, Rissler, Marianne, additional, Rissler, Vendela, additional, Agerstam, Helena, additional, Järås, Marcus, additional, Lilljebjörn, Henrik, additional, and Fioretos, Thoas, additional

Published
2022
Full Text
View/download PDF

27. Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Author

Ngai, Lok Lam, primary, Hanekamp, Diana, additional, Janssen, Fleur, additional, Carbaat-Ham, Jannemieke, additional, Hofland, Maaike A.M., additional, Fayed, Mona M.H.E, additional, Kelder, Angèle, additional, Oudshoorn-van Marsbergen, Laura, additional, Scholten, Willemijn J., additional, Snel, Alexander N., additional, Bachas, Costa, additional, Tettero, Jesse M., additional, Breems, Dimitri A., additional, Fischer, Thomas, additional, Gjertsen, Bjørn Tore, additional, Griškevičius, Laimonas, additional, Juliusson, Gunnar, additional, Maertens, Johan A., additional, Manz, Markus G, additional, Pabst, Thomas, additional, Passweg, Jakob R., additional, Porkka, Kimmo, additional, Gradowska, Patrycja, additional, Lowenberg, Bob, additional, de Leeuw, David C., additional, Janssen, Jeroen J.W.M., additional, Ossenkoppele, Gert J., additional, and Cloos, Jacqueline, additional

Published
2022
Full Text
View/download PDF

28. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Author

Furstenau, Moritz, primary, Thus, Yvonne, additional, Robrecht, Sandra, additional, Mellink, Clemens, additional, Van Der Kevie-Kersemaekers, Anne-Marie, additional, Dubois, Julie M.N., additional, Von Tresckow, Julia, additional, Patz, Michaela, additional, Gregor, Michael, additional, Thornton, Patrick, additional, Staber, Philipp B., additional, Tadmor, Tamar, additional, Levin, Mark-David, additional, Da Cunha-Bang, Caspar, additional, Schneider, Christof, additional, Poulsen, Christian Bjørn, additional, Illmer, Thomas, additional, Schöttker, Björn, additional, Janssens, Ann, additional, Christiansen, Ilse, additional, Baumann, Michael, additional, Noesslinger, Thomas, additional, Regelink, Josien, additional, Dompeling, Ellen C, additional, Lindström, Vesa, additional, Juliusson, Gunnar, additional, Widmer, Anouk, additional, Goede, Jeroen Simon, additional, Goldschmidt, Neta, additional, Simon, Florian, additional, De Silva, Nisha, additional, Fink, Anna-Maria, additional, Fischer, Kirsten, additional, Wendtner, Clemens-Martin, additional, Ritgen, Matthias, additional, Brüggemann, Monika, additional, Tausch, Eugen, additional, Stilgenbauer, Stephan, additional, Eldering, Eric, additional, Niemann, Carsten Utoft, additional, Hallek, Michael, additional, Eichhorst, Barbara, additional, Kreuzer, Karl-Anton, additional, and Kater, Arnon P., additional

Published
2022
Full Text
View/download PDF

29. Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Author

Tettero, Jesse M., primary, Ngai, Lok Lam, additional, Bachas, Costa, additional, Breems, Dimitri A., additional, Fischer, Thomas, additional, Gjertsen, Bjørn Tore, additional, Gradowska, Patrycja, additional, Griskevicius, Laimonas, additional, Janssen, Jeroen J.W.M., additional, Juliusson, Gunnar, additional, Maertens, Johan A., additional, Manz, Markus G, additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Porkka, Kimmo, additional, Valk, Peter JM, additional, Lowenberg, Bob, additional, Ossenkoppele, Gert J., additional, and Cloos, Jacqueline, additional

Published
2022
Full Text
View/download PDF

30. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Author

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C, Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

31. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Author

Tettero, Jesse M., primary, Al-Badri, Waleed K. W., additional, Ngai, Lok Lam, additional, Bachas, Costa, additional, Breems, Dimitri A., additional, van Elssen, Catharina H. M. J., additional, Fischer, Thomas, additional, Gjertsen, Bjorn T., additional, van Gorkom, Gwendolyn N. Y., additional, Gradowska, Patrycja, additional, Greuter, Marjolein J. E., additional, Griskevicius, Laimonas, additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus G., additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Porkka, Kimmo, additional, Löwenberg, Bob, additional, Ossenkoppele, Gert J., additional, Janssen, Jeroen J. W. M., additional, and Cloos, Jacqueline, additional

Published
2022
Full Text
View/download PDF

32. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications

Author

Nilsson, Christer, primary, Linde, Fredrika, additional, Hulegårdh, Erik, additional, Garelius, Hege, additional, Lazarevic, Vladimir, additional, Antunovic, Petar, additional, Cammenga, Jörg, additional, Deneberg, Stefan, additional, Eriksson, Anna, additional, Jädersten, Martin, additional, Björkvall, Cecilia Kämpe, additional, Möllgård, Lars, additional, Wennström, Lovisa, additional, Ölander, Emma, additional, Höglund, Martin, additional, Juliusson, Gunnar, additional, and Lehmann, Sören, additional

Published
2022
Full Text
View/download PDF

33. Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial

Author

Jädersten, Martin, primary, Lilienthal, Ingrid, additional, Tsesmetzis, Nikolaos, additional, Lourda, Magda, additional, Bengtzén, Sofia, additional, Bohlin, Anna, additional, Arnroth, Cornelia, additional, Erkers, Tom, additional, Seashore‐Ludlow, Brinton, additional, Giraud, Géraldine, additional, Barkhordar, Giti S., additional, Tao, Sijia, additional, Fogelstrand, Linda, additional, Saft, Leonie, additional, Östling, Päivi, additional, Schinazi, Raymond F., additional, Kim, Baek, additional, Schaller, Torsten, additional, Juliusson, Gunnar, additional, Deneberg, Stefan, additional, Lehmann, Sören, additional, Rassidakis, Georgios Z., additional, Höglund, Martin, additional, Henter, Jan‐Inge, additional, and Herold, Nikolas, additional

Published
2022
Full Text
View/download PDF

35. A risk score based on real-world data to predict early death in acute promyelocytic leukemia

Author

Osterroos, Albin, Maia, Tania, Eriksson, Anna, Jädersten, Martin, Lazarevic, Vladimir, Wennström, Lovisa, Antunovic, Petar, Cammenga, Jörg, Deneberg, Stefan, Lorenz, Fryderyk, Möllgård, Lars, Uggla, Bertil, Ölander, Emma, Aguiar, Eliana, Trigo, Fernanda, Höglund, Martin, Juliusson, Gunnar, Lehmann, Sören, Osterroos, Albin, Maia, Tania, Eriksson, Anna, Jädersten, Martin, Lazarevic, Vladimir, Wennström, Lovisa, Antunovic, Petar, Cammenga, Jörg, Deneberg, Stefan, Lorenz, Fryderyk, Möllgård, Lars, Uggla, Bertil, Ölander, Emma, Aguiar, Eliana, Trigo, Fernanda, Höglund, Martin, Juliusson, Gunnar, and Lehmann, Sören

Abstract

With increasingly effective treatments, early death (ED) has become the predominant reason for therapeutic failure in patients with acute promyelocytic leukemia (APL). To better prevent ED, patients with high-risk of ED must be identified. Our aim was to develop a score that predicts the risk of ED in a real-life setting. We used APL patients in the population based Swedish AML Registry (n=301) and a Portuguese hospital-based registry (n=129) as training and validation cohorts, respectively. The cohorts were comparable with respect to age (median, 54 and 53 years) and ED rate (19.6% and 18.6%). The score was developed by logistic regression analyses, risk-per-quantile assessment and scoring based on ridge regression coefficients from multivariable penalized logistic regression analysis. White blood cell count, platelet count and age were selected by this approach as the most significant variables for predicting ED. The score identified low-, high-and very high-risk patients with ED risks of 4.8%, 20.2% and 50.9% respectively in the training cohort and with 6.7%, 25.0% and 36.0% as corresponding values for the validation cohort. The score identified an increased risk of ED already at sub-normal and normal white blood cell counts and, consequently, it was better at predicting ED risk than the Sanz score (AUROC 0.77 vs. 0.64). In summary, we here present an externally validated and population-based risk score to predict ED risk in a real-world setting, identifying patients with the most urgent need of aggressive ED prevention. The results also suggest that increased vigilance for ED is already necessary at sub-normal/normal white blood cell counts., Funding Agencies|Swedish Association of Local Authorities and Regions; Swedish Cancer Society; Region Skane; Regionalt Cancercentrum Syd

Published
2022
Full Text
View/download PDF

36. Regional differences in treatment and outcome for myeloma patients in Sweden : A population based Swedish myeloma register study

Author

Walinder, Goran, Genell, Anna, Juliusson, Gunnar, Svensson, Ronald, Santamaria, Antonio Izarra, Crafoord, Jacob, Carlson, Kristina, Knut-Bojanowska, Dorota, Veskovski, Ljupco, Lauri, Birgitta, Lund, Johan, Turesson, Ingemar, Hansson, Markus, Blimark, Cecilie Hveding, Nahi, Hareth, Walinder, Goran, Genell, Anna, Juliusson, Gunnar, Svensson, Ronald, Santamaria, Antonio Izarra, Crafoord, Jacob, Carlson, Kristina, Knut-Bojanowska, Dorota, Veskovski, Ljupco, Lauri, Birgitta, Lund, Johan, Turesson, Ingemar, Hansson, Markus, Blimark, Cecilie Hveding, and Nahi, Hareth

Abstract

Background We wanted to evaluate if health care for multiple myeloma (MM) patients is equal in different regions of Sweden. Aim To study differences in survival for MM depending on health care region and early use of modern treatment. Methods and results Data from the Swedish Myeloma Register from patients diagnosed between 2008 and 2017 was used. Cohorts were defined by the six healthcare regions (labeled A-F) in Sweden and modern initial treatment was defined as including certain drug combinations. To adjust for time to treatment bias, survival analyses were performed also for patients alive 6 months after diagnosis. In all treated MM patients (n = 5326), we observed a superior overall survival (OS) for region A compared to all other regions (p < .01 for all respectively). After adjusting for time to treatment there was also a superior survival in the region with highest use of modern initial treatment (region A) compared to the regions defined in the study as having intermediate and low use (p < .01 for both). In patients receiving autologous stem cell transplantation (ASCT) a superior survival was observed for region A compared to all regions besides region B. Similar results were seen when adjusting for a time to treatment bias. In patients not receiving ASCT, 75 years or older and adjusted for time to treatment bias, a difference was noted only between region A and E (log rank p = .04, HR 1.2, CI 1.00-1.44, p = .06). In multivariate analyses including age, international staging system stage and time period of diagnosis, differences in survival remained for patients receiving ASCT between region A versus C, D, E and F (p = .01, p < .01, p < .01, p = .03). Conclusion We observed a superior survival in region A for patients receiving ASCT. Explanations may be higher usage of modern initial treatment or regional residual confounding. For patients not receiving ASCT, 75 years or older, differences in survival could be adjusted for., Funding Agencies|CancerfondenSwedish Cancer Society

Published
2022
Full Text
View/download PDF

37. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia : Results from the HEAT-AML trial

Author

Jadersten, Martin, Lilienthal, Ingrid, Tsesmetzis, Nikolaos, Lourda, Magda, Bengtzen, Sofia, Bohlin, Anna, Arnroth, Cornelia, Erkers, Tom, Seashore-Ludlow, Brinton, Giraud, Geraldine, Barkhordar, Giti S., Tao, Sijia, Fogelstrand, Linda, Saft, Leonie, Ostling, Paivi, Schinazi, Raymond F., Kim, Baek, Schaller, Torsten, Juliusson, Gunnar, Deneberg, Stefan, Lehmann, Sören, Rassidakis, Georgios Z., Höglund, Martin, Henter, Jan-Inge, Herold, Nikolas, Jadersten, Martin, Lilienthal, Ingrid, Tsesmetzis, Nikolaos, Lourda, Magda, Bengtzen, Sofia, Bohlin, Anna, Arnroth, Cornelia, Erkers, Tom, Seashore-Ludlow, Brinton, Giraud, Geraldine, Barkhordar, Giti S., Tao, Sijia, Fogelstrand, Linda, Saft, Leonie, Ostling, Paivi, Schinazi, Raymond F., Kim, Baek, Schaller, Torsten, Juliusson, Gunnar, Deneberg, Stefan, Lehmann, Sören, Rassidakis, Georgios Z., Höglund, Martin, Henter, Jan-Inge, and Herold, Nikolas

Abstract

Background Treatment of newly diagnosed acute myeloid leukaemia (AML) is based on combination chemotherapy with cytarabine (ara-C) and anthracyclines. Five-year overall survival is below 30%, which has partly been attributed to cytarabine resistance. Preclinical data suggest that the addition of hydroxyurea potentiates cytarabine efficacy by increasing ara-C triphosphate (ara-CTP) levels through targeted inhibition of SAMHD1. Objectives In this phase 1 trial, we evaluated the feasibility, safety and efficacy of the addition of hydroxyurea to standard chemotherapy with cytarabine/daunorubicin in newly diagnosed AML patients. Methods Nine patients were enrolled and received at least two courses of ara-C (1 g/m(2)/2 h b.i.d. d1-5, i.e., a total of 10 g/m(2) per course), hydroxyurea (1-2 g d1-5) and daunorubicin (60 mg/m(2) d1-3). The primary endpoint was safety; secondary endpoints were complete remission rate and measurable residual disease (MRD). Additionally, pharmacokinetic studies of ara-CTP and ex vivo drug sensitivity assays were performed. Results The most common grade 3-4 toxicity was febrile neutropenia (100%). No unexpected toxicities were observed. Pharmacokinetic analyses showed a significant increase in median ara-CTP levels (1.5-fold; p = 0.04) in patients receiving doses of 1 g hydroxyurea. Ex vivo, diagnostic leukaemic bone marrow blasts from study patients were significantly sensitised to ara-C by a median factor of 2.1 (p = 0.0047). All nine patients (100%) achieved complete remission, and all eight (100%) with validated MRD measurements (flow cytometry or real-time quantitative polymerase chain reaction [RT-qPCR]) had an MRD level <0.1% after two cycles of chemotherapy. Treatment was well-tolerated, and median time to neutrophil recovery >1.0 x 10(9)/L and to platelet recovery >50 x 10(9)/L after the start of cycle 1 was 19 days and 22 days, respectively. Six of nine patients underwent allogeneic haematopoietic stem-cell transplantation (al

Published
2022
Full Text
View/download PDF

38. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia:An outcome- and cost-analysis

Author

Tettero, Jesse M., Al-Badri, Waleed K.W., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., van Elssen, Catharina H.M.J., Fischer, Thomas, Gjertsen, Bjorn T., van Gorkom, Gwendolyn N.Y., Gradowska, Patrycja, Greuter, Marjolein J.E., Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, Ossenkoppele, Gert J., Janssen, Jeroen J.W.M., Cloos, Jacqueline, Tettero, Jesse M., Al-Badri, Waleed K.W., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., van Elssen, Catharina H.M.J., Fischer, Thomas, Gjertsen, Bjorn T., van Gorkom, Gwendolyn N.Y., Gradowska, Patrycja, Greuter, Marjolein J.E., Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, Ossenkoppele, Gert J., Janssen, Jeroen J.W.M., and Cloos, Jacqueline

Abstract

Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment for MRD-negative patients in the ELN-2017 intermediate risk group. Currently, measurement of MFC-MRD in bone marrow is used for clinical decision making after 2 cycles of induction chemotherapy. However, measurement after 1 cycle has also been shown to have prognostic value, so the optimal time point remains a question of debate. We assessed the independent prognostic value of MRD results at either time point and concordance between these for 273 AML patients treated within and according to the HOVON-SAKK 92, 102, 103 and 132 trials. Cumulative incidence of relapse, event free survival and overall survival were significantly better for MRD-negative (<0.1%) patients compared to MRD-positive patients after cycle 1 and cycle 2 (p ≤ 0.002, for all comparisons). A total of 196 patients (71.8%) were MRD-negative after cycle 1, of which the vast majority remained negative after cycle 2 (180 patients; 91.8%). In contrast, of the 77 MRD-positive patients after cycle 1, only 41 patients (53.2%) remained positive. A cost reduction of –€571,751 per 100 patients could be achieved by initiating the donor search based on the MRD-result after cycle 1. This equals to a 50.7% cost reduction compared to the current care strategy in which the donor search is initiated for all patients. These results show that MRD after cycle 1 has prognostic value and is highly concordant with MRD status after cycle 2. When MRD-MFC is used to guide consolidation treatment (allo vs non-allo) in intermediate risk patients, allogeneic donor search may be postponed or omitted after cycle 1. Since the majority of MRD-negative patients remain negative after cycle 2, this could safely reduce the number of all

Published
2022

39. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Author

Tettero, Jesse M, Al-Badri, Waleed K W, Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A, van Elssen, Catharina H M J, Fischer, Thomas, Gjertsen, Bjorn T, van Gorkom, Gwendolyn N Y, Gradowska, Patrycja, Greuter, Marjolein J E, Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, Ossenkoppele, Gert J, Janssen, Jeroen J W M, Cloos, Jacqueline, Tettero, Jesse M, Al-Badri, Waleed K W, Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A, van Elssen, Catharina H M J, Fischer, Thomas, Gjertsen, Bjorn T, van Gorkom, Gwendolyn N Y, Gradowska, Patrycja, Greuter, Marjolein J E, Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, Ossenkoppele, Gert J, Janssen, Jeroen J W M, and Cloos, Jacqueline

Abstract

Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment for MRD-negative patients in the ELN-2017 intermediate risk group. Currently, measurement of MFC-MRD in bone marrow is used for clinical decision making after 2 cycles of induction chemotherapy. However, measurement after 1 cycle has also been shown to have prognostic value, so the optimal time point remains a question of debate. We assessed the independent prognostic value of MRD results at either time point and concordance between these for 273 AML patients treated within and according to the HOVON-SAKK 92, 102, 103 and 132 trials. Cumulative incidence of relapse, event free survival and overall survival were significantly better for MRD-negative (<0.1%) patients compared to MRD-positive patients after cycle 1 and cycle 2 (p ≤ 0.002, for all comparisons). A total of 196 patients (71.8%) were MRD-negative after cycle 1, of which the vast majority remained negative after cycle 2 (180 patients; 91.8%). In contrast, of the 77 MRD-positive patients after cycle 1, only 41 patients (53.2%) remained positive. A cost reduction of -€571,751 per 100 patients could be achieved by initiating the donor search based on the MRD-result after cycle 1. This equals to a 50.7% cost reduction compared to the current care strategy in which the donor search is initiated for all patients. These results show that MRD after cycle 1 has prognostic value and is highly concordant with MRD status after cycle 2. When MRD-MFC is used to guide consolidation treatment (allo vs non-allo) in intermediate risk patients, allogeneic donor search may be postponed or omitted after cycle 1. Since the majority of MRD-negative patients remain negative after cycle 2, this could safely reduce the number of allogenei

Published
2022

40. Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study

Author

Wålinder, Göran, primary, Genell, Anna, additional, Juliusson, Gunnar, additional, Svensson, Ronald, additional, Santamaria, Antonio Izarra, additional, Crafoord, Jacob, additional, Carlson, Kristina, additional, Knut‐Bojanowska, Dorota, additional, Veskovski, Ljupco, additional, Lauri, Birgitta, additional, Lund, Johan, additional, Turesson, Ingemar, additional, Hansson, Markus, additional, Blimark, Cecilie Hveding, additional, and Nahi, Hareth, additional

Published
2022
Full Text
View/download PDF

42. A risk score based on real-world data to predict early death in acute promyelocytic leukemia

Author

Österroos, Albin, primary, Maia, Tânia, additional, Eriksson, Anna, additional, Jädersten, Martin, additional, Lazarevic, Vladimir, additional, Wennström, Lovisa, additional, Antunovic, Petar, additional, Cammenga, Jörg, additional, Deneberg, Stefan, additional, Lorenz, Fryderyk, additional, Möllgård, Lars, additional, Uggla, Bertil, additional, Ölander, Emma, additional, Aguiar, Eliana, additional, Trigo, Fernanda, additional, Höglund, Martin, additional, Juliusson, Gunnar, additional, and Lehmann, Sören, additional

Published
2022
Full Text
View/download PDF

43. A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Author

Eichhorst, Barbara, primary, Niemann, Carsten, additional, Kater, Arnon P., additional, Fürstenau, Moritz, additional, Von Tresckow, Julia, additional, Zhang, Can, additional, Robrecht, Sandra, additional, Gregor, Michael, additional, Juliusson, Gunnar, additional, Thornton, Patrick, additional, Staber, Philipp B., additional, Tadmor, Tamar, additional, Lindström, Vesa, additional, Da Cunha-Bang, Caspar, additional, Schneider, Christof, additional, Poulsen, Christian Bjørn, additional, Illmer, Thomas, additional, Schöttker, Björn, additional, Janssens, Ann, additional, Christiansen, Ilse, additional, Noesslinger, Thomas, additional, Baumann, Michael, additional, van der Klift, Marjolein, additional, Jaeger, Ulrich, additional, Frederiksen, Henrik, additional, Leijs, Maria B.L., additional, Hoogendoorn, Mels, additional, Lotfi, Kourosh, additional, Hebart, Holger, additional, Gaska, Tobias, additional, Koene, Harry R., additional, Simon, Florian, additional, De Silva, Nisha, additional, Fink, Anna-Maria, additional, Fischer, Kirsten, additional, Wendtner, Clemens-Martin, additional, Kreuzer, Karl-Anton, additional, Ritgen, Matthias, additional, Brüggemann, Monika, additional, Tausch, Eugen, additional, Levin, Mark-David, additional, Van Oers, Marinus H.J., additional, Geisler, Christian H., additional, Stilgenbauer, Stephan, additional, and Hallek, Michael, additional

Published
2021
Full Text
View/download PDF

44. P-184: Regional differences in treatment and outcome for myeloma patients in Sweden: a population based Swedish Myeloma Register study

Author

Wålinder, Göran, primary, Genell, Anna, additional, Juliusson, Gunnar, additional, Svensson, Ronald, additional, Santamaria, Antonio, additional, Crafoord, Jacob, additional, Carlson, Kristina, additional, Knut-Bojanowska, Dorota, additional, Veskovski, Ljupco, additional, Lauri, Birgitta, additional, Lund, Johan, additional, Turesson, Ingemar, additional, Hansson, Markus, additional, Blimark, Cecilie Hveding, additional, and Nahi, Hareth, additional

Published
2021
Full Text
View/download PDF

45. First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Author

Fürstenau, Moritz, Ritgen, Matthias, Robrecht, Sandra, Von Tresckow, Julia, Zhang, Can, Schilhabel, Anke, Gregor, Michael, Thornton, Patrick, Staber, Philipp Bernhard, Tadmor, Tamar, Lindström, Vesa, Juliusson, Gunnar, Janssens, Ann, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Goldschmidt, Neta, Vandenberghe, Elisabeth, Rossi, Davide, Benz, Rudolf A., Heintel, Daniel, Poulsen, Christian Bjørn, Christiansen, Ilse, Frederiksen, Henrik, Enggaard, Lisbeth, Posthuma, Eduardus, Issa, Djamila, Visser, Hein, Bellido, Mar, Kutsch, Nadine, Dürig, Jan, Stehle, Alexander, Voehringer, Matthias C., Böttcher, Sebastian, Schulte, Clemens, Simon, Florian, Fink, Anna-Maria, Fischer, Kirsten, Holmes, Emily, Kreuzer, Karl-Anton, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Hallek, Michael, Kater, Arnon P., Niemann, Carsten Utoft, and Eichhorst, Barbara F.

Published
2023
Full Text
View/download PDF

46. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Author

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M.N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C, Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Published
2022
Full Text
View/download PDF

47. Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Author

Ngai, Lok Lam, Veenstra, Coen R., Gradowska, Patrycja, Kelder, Angèle, Scholten, Willemijn, Snel, Alexander N., Tettero, Jesse M., Bachas, Costa, Breems, Dimitri, Fischer, Thomas, Gjertsen, Bjorn T., Griškevičius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Alhan, Canan, Westers, Theresia M., Valk, Peter J. M., de Leeuw, David C., Lowenberg, Bob, Ossenkoppele, Gert, Cloos, Jacqueline, and van de Loosdrecht, Arjan A.

Abstract

Diagnosis of myelodysplastic syndromes (MDS) and accurate risk assessment to tailor treatment remains challenging. High-risk MDS (hrMDS) patients who are fit enough may benefit from intensive chemotherapy followed by post-remission consolidation. The HOVON-SAKK (HO) acute myeloid leukemia (AML) trials, designed to test novel drug combinations with an intensive treatment regimen, included hrMDS patients (RAEB and RAEB-T). Since these HO-trials have been executed with large patient cohorts for many years, they offer the unique possibility to study the outcome, risk classification, and relevance of measurable residual disease (MRD) in hrMDS. A pooled database is available from HOVON-SAKK of patients who were treated with intensive chemotherapy (studies containing MDS patients with IPSS ≥ 1.5 HO42A, HO81, HO92, HO102, and IPSS-R > 4.5 HO103, HO132).

Published
2023
Full Text
View/download PDF

48. Vaccine-Preventable Infections in Multiple Myeloma: A Population-Based Study on 8672 Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Author

Einarsdottir, Sigrun, Sverrisdottir, Ingigerdur, Villegas Scivetti, Mariana, Day, Christopher, Turesson, Ingemar, Juliusson, Gunnar, Carlson, Kristina Elisabet, Larfors, Gunnar, and Blimark, Cecilie Hveding

Abstract

Background: Infections are a major clinical problem in the management of multiple myeloma (MM) due to both disease and treatment related factors. Measures to prevent infection, such as vaccination, are therefore of paramount importance in the clinical care of MM patients. Data on vaccine-preventable infections in MM treated with modern therapy is sparse.

Published
2023
Full Text
View/download PDF

49. Risk of Infections in Multiple Myeloma in the Era of Novel Agents, a Population-Based Study Based on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Author

Blimark, Cecilie Hveding, Carlson, Kristina, Day, Christopher, Einarsdottir, Sigrun, Juliusson, Gunnar, Karma, Moshtak, Knut-Bojanowska, Dorota, Larfors, Gunnar, Turesson, Ingemar, Villegas Scivetti, Mariana, and Sverrisdottir, Ingigerdur

Abstract

Introduction

Published
2023
Full Text
View/download PDF

50. The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Author

Al-Sawaf, Othman, Fürstenau, Moritz, Giza, Adam, Robrecht, Sandra, Von Tresckow, Julia, Fink, Anna Maria, Simon, Florian, Tausch, Eugen, Schneider, Christof, Sivcheva, Liliya, Schwarer, Anthony, Loscertales, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah R., Juliusson, Gunnar, Da Cunha-Bang, Caspar, Illmer, Thomas, Gregor, Michael, Thornton, Patrick, Janssens, Ann, Tadmor, Tamar, Lindström, Vesa, Staber, Philipp Bernhard, Levin, Mark-David, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Ritgen, Matthias, Stilgenbauer, Stephan, Kater, Arnon P., Niemann, Carsten Utoft, Fischer, Kirsten, Eichhorst, Barbara F., and Hallek, Michael

Abstract

Introduction

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results